

LIST OF TABLES

		Pag€
Table I	Number of patients whose data were used for analyses in different chapters of Report No. 12	10
Table 1.1	Body mass index at diagnosis (N=4,820)	19
Table 1.2	Family history of breast cancer at diagnosis (N=4,820)	19
Table 1.3	Personal history of other tumours at diagnosis (N=4,820)	20
Table 1.4	Origins of malignant tumours reported by patients (N=94)	20
Table 1.5	History of benign breast disease at diagnosis (N=4,820)	21
Table 1.6	Menarche, menopause and reproductive history at diagnosis	21
Table 1.7	Number of live births reported by patients (N=3,565)	22
Table 1.8	Use of hormonal contraceptives at diagnosis (N=4,820)	22
Table 1.9	Use of hormone replacement therapy at diagnosis (N=2,840)	22
Table 1.10	Ten most common risk factors for breast cancer in patient cohort (N=4,820)	23
Table 1.11	Breast screening habits by age group (N=4,742)	24
Table 1.12	Breast screening habits by education level (N=4,789)	25
Table 1.13	Breast screening habits by monthly household income (HK\$) (N=2,287)	26
Table 1.14	Breast screening habits by district of residence (N=4,573)	27
Table 2.1	Method of first breast cancer detection by type of medical service users (N=3,824)	33
Table 2.2	Method of first breast cancer detection by type of cancer (N=3,796)	34
Table 2.3	Method of first breast cancer detection by cancer stage (N=3,580)	34
Table 2.4	Time interval between onset of symptoms and first medical consultation for patients who self-detected* their cancer (N=868)	35
Table 2.5	Time interval between onset of symptoms and first medical consultation for patients who self-detected* their cancer by type of medical service users (N=868)	35
Table 2.6	Cancer stage at diagnosis among self-detected* patients by time interval between onset of symptoms and first medical consultation (N=759)	36
Table 2.7	Number of patients and breast cancer cases in the patient cohort	36
Table 2.8	Sensitivity and diagnostic results of breast imaging tests (N=3,998)	37
Table 2.9	Mammographic findings of patients diagnosed through mammography (N=3,193)	38
Table 2.10	Mammographic density of breasts of patients diagnosed through mammogram by age group (N=1,837)	38
Table 2.11	Sensitivity and diagnostic results of breast tissue biopsies (N=3,998)	39
Table 2.12	Method of cancer staging among invasive breast cancer patients (N=1,471)	40
Table 2.13	Histological type of invasive breast cancer (N=3,318)	43



		Page
Table 2.14	Grading, multifocality and multicentricity of invasive breast cancer (N=3,318)	43
Table 2.15	Biological characteristics of invasive breast cancer (N=3,318)	44
Table 2.16	Biological subtypes of invasive tumours by cancer stage (N=2,945)	45
Table 2.17	Histological type, grading, multifocality and multicentricity of in situ breast cancer (N=520)	46
Table 2.18	Biological characteristics of in situ breast cancer (N=520)	46
Table 2.19	Use of surgery for patients with invasive or in situ cancer	48
Table 2.20	Coverage of regional lymph nodes by adjuvant locoregional radiotherapy (N=1,184)	52
Table 2.21	Use of chemotherapy by age group and cancer stage at diagnosis (N=3,187)	53
Table 2.22	Number of treatment modalities by cancer stage (N=3,747)	61
Table 2.23	Follow-up of 17,877 patients	62
Table 2.24	Locoregional recurrence by type of surgery received and cancer stage at diagnosis	63
Table 2.25	Sites involved in locoregional recurrence (N=579)	63
Table 2.26	Organs involved in distant recurrence (N=706)	64
Table 2.27	Time for organ specific metastasis and distribution of the biological subtypes of patients	64
Table 2.28	Locoregional and distant recurrence among invasive breast cancer patients by cancer stage (N=14,751)	65
Table 2.29	Characteristics of breast cancer-specific deaths (N=226)	66
Table 3.1	Five most common forms of discomfort after surgery (N=3,348)	70
Table 3.2	Five most common forms of discomfort after radiotherapy (N=1,839)	70
Table 3.3	Five most common forms of discomfort after chemotherapy (N=1,630)	71
Table 3.4	Five most common forms of discomfort after endocrine therapy (N=2,043)	71
Table 3.5	Five most common forms of discomfort after anti-HER2 targeted therapy (N=478)	72
Table 3.6	Psychosocial impact of breast cancer	73
Table 3.7	Psychosocial adjustments and coping strategies for survivorship	74



LIST OF FIGURES

		Page
Figure I	Distribution of year of diagnosis of HKBCR participants	6
Figure II	Sources of patient consent in HKBCR reports	10
Figure 1.1	Distribution of age at diagnosis (N=20,057)	15
Figure 1.2	Occupation of patient cohort (N=4,820)	16
Figure 1.3	Education level of patient cohort (N=4,820)	16
Figure 1.4	Monthly household income (HK\$) of patient cohort (N=2,287)	16
Figure 1.5	District of residence of patient cohort (N=4,820)	17
Figure 1.6	Bra band size of patient cohort (N=4,820)	17
Figure 1.7	Bra cup size of patient cohort (N=4,820)	17
Figure 1.8	Dietary habits at diagnosis (N=4,820)	18
Figure 1.9	Exercise habits at diagnosis (N=4,820)	18
Figure 1.10	Stress level at diagnosis (N=4,820)	19
Figure 1.11	Distribution of risk factors among patients at diagnosis (N=4,820)	23
Figure 2.1	Method of first breast cancer detection in the patient cohorts (N=18,602)	33
Figure 2.2	Major presenting symptoms of self-detected* breast cancer in the patient cohort (N=3,059)	34
Figure 2.3	Locations of malignant tumour on breasts within the patient cohort (N=3,998)	37
Figure 2.4	Mammographic density of breasts of patients diagnosed through mammogram (N=1,869)	38
Figure 2.5	Cancer stage at diagnosis (N=3,998)	41
Figure 2.6	Distribution of tumour size (cm) of invasive breast cancer (N=2,682)	41
Figure 2.7	Number of positive axillary lymph nodes among patients with invasive breast cancer (N=3,064)	42
Figure 2.8	Distribution of tumour size (cm) of in situ breast cancer (N=418)	42
Figure 2.9	Type of surgery by age group (N=3,798)	49
Figure 2.10	Type of surgery by invasive tumour size (N=2,843)	49
Figure 2.11	Type of surgery by cancer stage (N=3,669)	49
Figure 2.12	Type of surgery by type of medical service (N=3,713)	49
Figure 2.13	Type of nodal surgery by clinical nodal status (N=3,615)	50
Figure 2.14	Type of nodal surgery for invasive cancer by cancer stage (N=3,132)	50
Figure 2.15	Distribution of tumour size in invasive cancer with negative or positive nodal status (N=2,576)	50
Figure 2.16	Number of positive nodes by type of nodal surgery (N=3,049)	51
Figure 2.17	Use of locoregional radiotherapy among patients who underwent breast-conserving	52



		Page
Figure 2.18	Use of locoregional radiotherapy among patients who underwent mastectomy by cancer stage (N=2,047)	52
Figure 2.19	Chemotherapy treatment by cancer stage (N=3,217)	53
Figure 2.20	Generation of chemotherapy drugs used by biological subtype in neoadjuvant setting (N=358)	54
Figure 2.21	Type of first generation chemotherapy drugs (non-HER2 regimen) used in adjuvant setting (N=112)	55
Figure 2.22	Type of second generation chemotherapy drugs (non-HER2 regimen) used in adjuvant setting $(N=378)$	55
Figure 2.23	Type of third generation chemotherapy drugs (non-HER2 regimen) used in adjuvant setting (N=438)	55
Figure 2.24	Type of HER2 regimens used in adjuvant setting (N=211)	55
Figure 2.25	Generation of chemotherapy drugs used by biological subtype in adjuvant setting (N=1,182)	56
Figure 2.26	Generation of chemotherapy drugs used by cancer stage in adjuvant setting (N=1,256)	57
Figure 2.27	Generation of chemotherapy drugs used by biological subtype in palliative setting (N=63)	58
Figure 2.28	Use of endocrine therapy by cancer stage (N=3,747)	59
Figure 2.29	Forms of endocrine therapy by age group (N=2,360)	59
Figure 2.30	Use of anti-HER2 targeted therapy in HER2 positive patients by cancer stage (N=511)	60
Figure 2.31	Type of complementary and alternative therapies used (N=950)	61
Figure 3.1	Level of physical discomfort after surgery (N=17,228)	69
Figure 3.2	Level of physical discomfort by type of surgery (N=3,330)	70
Figure 3.3	Level of physical discomfort after radiotherapy (N=1,839)	70
Figure 3.4	Level of physical discomfort after radiotherapy by irradiated regions (N=1,009)	70
Figure 3.5	Level of physical discomfort after chemotherapy (N=1,630)	71
Figure 3.6	Level of physical discomfort after endocrine therapy (N=2,043)	71
Figure 3.7	Level of physical discomfort after anti-HER2 targeted therapy (N=478)	72
Figure 3.8	Level of physical discomfort after complementary and alternative therapies (N=931)	72
Figure 3.9	Change in outlook on life by age group (N=3,257)	73
Figure 3.10	Change in self-image by age group (N=3,249)	74
Figure 3.11	Level of worry about recurrence by age group (N=3,222)	74